Trevi Therapeutics, Inc.
A biopharmaceutical company focused on developing and commercializing investigational drugs aimed at treating severe neurologically mediated conditions. The company is developing and working toward marketing approval of drugs for the treatment of prurigo nodularis and chronic prurigo associated with chronic cough in patients with idiopathic pulmonary fibrosis. Based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | Connecticut |
Employees | 25 |
Founded | 2011 |
Financials | |
|---|---|
Market Capitalization | 197.22M |
Revenue | |
Operating Income | -38.27M |
Operating Margin | |
Net Income | -33.57M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4306 / 5373 |
Sector : Healthcare | 653 / 1144 |
Industry : Biotechnology | 284 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3638 / 5565 |
Sector : Healthcare | 591 / 1182 |
Industry : Biotechnology | 297 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4108 / 5436 |
Sector : Healthcare | 610 / 1164 |
Industry : Biotechnology | 271 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4731 / 5330 |
Sector : Healthcare | 925 / 1174 |
Industry : Biotechnology | 467 / 667 |